Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections.

Drugs
Lily P H Yang, Susan J Keam

Abstract

Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding meticillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months. In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. Retapamulin has a novel site of action on bacterial ribosomes. In clinical trials in patients with impetigo, topical retapamulin 1% ointment twice daily for 5 days (the approved regimen) was superior to placebo; treatment with retapamulin was noninferior to that with topical fusidic acid. In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cefalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. Retapamulin was well tolerated in both paediatric and adult patients, and the majority of adverse events were of mild to moderate severity. Thus, the introduction of topical retapamulin 1% ointment extends th...Continue Reading

References

Apr 1, 1990·The Journal of Antimicrobial Chemotherapy·B D Cookson
May 1, 1997·Antimicrobial Agents and Chemotherapy·J E FinlayJ A Poupard
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·J HarocheN El Solh
Dec 6, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M Semret, M A Miller
May 15, 2002·Diagnostic Microbiology and Infectious Disease·L M DeshpandeUNKNOWN SENTRY Antimicrobial Surveillance Program Participants Group
Jun 8, 2002·BMJ : British Medical Journal·Erwin M Brown, Richard Wise
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·A UptonH Heffernan
Jun 6, 2003·The British Journal of Dermatology·M Shah, M Mohanraj
Jan 8, 2004·Archives of Disease in Childhood·D Dobie, J Gray
Sep 25, 2004·BMJ : British Medical Journal·Sander Koning, Johannes C van der Wouden
Jun 3, 2005·Pediatrics·Sheldon WinnickDavid Toll
Sep 17, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·G Perera, R Hay
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L StevensUNKNOWN Infectious Diseases Society of America
Jan 5, 2006·Molecular Microbiology·Alexander John O'Neill, Ian Chopra
Mar 9, 2006·JAMA : the Journal of the American Medical Association·Gilda PiaggioUNKNOWN CONSORT Group
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Ronald N JonesJames E Ross
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Stephen RittenhouseDavid Payne
Feb 28, 2007·Antimicrobial Agents and Chemotherapy·A J O'NeillI Chopra
Mar 14, 2007·The Journal of Antimicrobial Chemotherapy·M-F OdouL Dubreuil
Oct 4, 2007·Dermatology : International Journal for Clinical and Investigative Dermatology·Arnold P OranjeUNKNOWN TOC100224 Study Team

❮ Previous
Next ❯

Citations

Nov 1, 2008·American Journal of Clinical Dermatology·Lily P H Yang, Susan J Keam
Oct 11, 2013·Journal of the Royal Army Medical Corps·Lucy Lamb, M Morgan
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·F Kate GouldUNKNOWN MRSA Working Party of the British Society for Antimicrobial Chemotherapy
May 16, 2019·Nature Chemistry·Evijola LlabaniPaul J Hergenrother
Sep 22, 2009·Applied and Environmental Microbiology·Sreedhar KilaruGary D Foster
Mar 24, 2010·Expert Opinion on Pharmacotherapy·Christina SchnoppMartin Mempel
Jul 15, 2015·Chemical Society Reviews·Tegan P Stockdale, Craig M Williams
Feb 4, 2012·Pediatric Dermatology·Scott BangertAdelaide A Hebert
Jul 3, 2018·The Annals of Pharmacotherapy·Christopher WrenLea S Eiland
Aug 27, 2009·Contact Dermatitis·Peter C Schalock
Dec 6, 2011·Expert Opinion on Therapeutic Patents·Herbert A Kirst
Mar 18, 2021·Expert Opinion on Drug Safety·Eugenio Galindo, Adelaide A Hebert
Mar 23, 2019·Microbiology Spectrum·Martin VestergaardHanne Ingmer
Apr 4, 2009·International Journal of Antimicrobial Agents·Ursula Theuretzbacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.